December 6th 2024
Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA approval.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Surprising Findings in Intratumor Heterogeneity Could Impact Cancer Treatment
December 23rd 2015A new study has analyzed intratumoral heterogeneity (ITH) in 12 cancer types and found a "tolerable" level of genomic instability, independent of cancer type, beyond which a cancer may become less aggressive.
Read More
Novel Immunotherapy for Pancreatic Cancer May Allow for Resection of the Unresectable
December 16th 2015The phase III PILLAR trial studying the novel immunotherapy, algenpantucel-L combined with chemotherapy in patients with locally advanced, unresectable pancreatic cancer, has completed enrollment with over 300 patients.
Read More
Stakeholders Urge Congress to Pass Screening Act for Colorectal Cancer
November 13th 2015A number of colorectal cancer care advocacy groups and the American Cancer of Radiology are lobbying Congress to pass the CT Colonography Screening for Colorectal Cancer Act, an initiative that could lower costs and increase screening rates.
Read More
Soil Bacteria Reduces Growth of Colorectal Cancer Cells in Preclinical Study
November 13th 2015Dead bacteria cells and bacteria excretions from Clostridium sporogenes have successfully been used to kill colorectcal cancer cells in a preclinical study performed by researchers at the Nanyang Technological University in Singapore.
Read More
Dr. John Zalcberg on Regorafenib in Refractory Advanced Oesophago-Gastric Cancer Patients
November 11th 2015John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.
Watch
Dr. Dirk Arnold on Sirflox and its Effect on Liver Metastases
October 28th 2015Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about sirflox and its phase III trials on whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.
Watch
Prostate Cancer Study Shows Hypofractionation Comparable to Standard Radiation in Low-risk Patients
October 21st 2015Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.
Read More
Everolimus Reduces Risk of Progression and Death in Lung/GI NETs
October 20th 2015Everolimus demonstrated a 52% reduction in the risk of progression or death in patients with lung/gastrointestinal neuroendocrine tumors, improving progression-free survival by 7.1 months compared with placebo.
Read More
Coordination of Care Based on Patient-Reported Outcomes Improves End-of-Life Care and Lowers Costs
October 19th 2015Coordinating radiation therapy teams and palliative care teams based on patient reported outcomes from University of Virginia Health System improved outpatient symptom management and decreased end-of-life hospitalizations, as well as costs of care for patients with late-stage cancer.
Read More
HCC Survival Impacted by Radiofrequency Ablation Dwell Time
October 5th 2015A more than 25-month improvement in overall survival was seen with lyso-thermosensitive liposomal doxorubicin (LTLD; ThermoDox) combined with optimized (?45 minutes dwell time) radiofrequency ablation in patients with hepatocellular carcinoma.
Read More
US-Ireland Partnership Aims to Penetrate the Impenetrable Pancreatic Tumor
September 18th 2015Researchers from United States and Ireland have formed a partnership to advance nanoparticle-based delivery systems that would not only drive sustained-release of cytotoxic agents, but could improve penetration of these treatments within the tumor and allow them to continue working for days or weeks.
Read More